Studies on oncoprotein-induced feedback: Basic and therapeutic implications
癌蛋白诱导反馈的研究:基本和治疗意义
基本信息
- 批准号:9186828
- 负责人:
- 金额:$ 102.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAllelesAttenuatedCell Death InductionCellsClinicalCombined Modality TherapyDataDependenceDevelopmentDoseDrug TargetingFRAP1 geneFeedbackGoalsKnowledgeLearningLogicMEKsMethodologyMutationNodalOncogenesOutputPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalProcessPropertyProteinsProto-Oncogene Proteins c-aktReceptor ActivationScheduleSignal PathwaySignal TransductionTherapeuticWorkactionable mutationantitumor effectbasecell transformationepigenetic regulationin vivoinhibitor/antagonistinsightmutantnovelsmall hairpin RNAsuccesstumor
项目摘要
PROJECT SUMMARY / ABSTRACT
We have established that oncoproteins which function as dysregulated components of mitogenic
signaling pathways cause marked feedback inhibition of physiologic signaling. Much of our recent work
has focused on understanding the implications of this phenomenon. Insensitivity to feedback inhibition
of receptor activation of wild type RAS is a common property of oncoproteins that activated ERK
signaling that is required for them to elevate ERK output. Second, elevated pathway output includes
elevated feedback inhibition of physiologic signaling pathways. This is a major determinant of the so-
called oncoprotein dependence of transformed cells. Third, feedback-dependent oncoprotein pathway
dependence reduces the robustness of the cell and creates a selection for mutations that activate
feedback-Inhibited pathways and restores robustness. This accounts for some of the secondary driver
mutations identified in tumors. Finally, inhibitors of oncoprotein-activated signaling have significant
antitumor activity, but also relieve feedback inhibition of physiologic mitogenic signaling pathways and
cause their reactivation. This attenuates their antitumor activity and creates a logic for inhibiting key
reactivated pathways in tumors exposed to inhibitors of oncoproteins. This strategy has had some early
clinical success and has become a paradigm for the development of rational combination therapies.
Despite these insights, we still know only few of the details of oncoprotein-induced feedback and its
relief by targeted inhibitors. We do know that these details vary as a function of tumor lineage and
which pathway component is mutationally activated. Moreover, the effects of relieving feedback also
vary depending on which node of the pathway is pharmacologically inhibited. We now plan to
comprehensively study feedback and its relief by nodal inhibitors, focusing on a few tumors and using
both methodologies biased by previous knowledge of normal signaling and unbiased shRNA screens.
We utilize selective inhibitors of PI3K, AKT, mTOR, RAF, MEK, ERK, and a novel allele-specific
inhibitor of RAS and study both short- and long-term adaptation, to determine whether some of the
effects of the latter are due to epigenetic regulation. The goal is to develop new effective combination
therapies based on these data and on in vivo studies to determine dose schedules that optimize
induction of cell death.
项目总结/摘要
我们已经证实,作为促有丝分裂素的失调成分发挥功能的癌蛋白,
信号传导途径引起生理信号传导的显著反馈抑制。我们最近的大部分工作
致力于理解这一现象的含义。对反馈抑制不敏感
野生型RAS的受体激活是激活ERK的癌蛋白的共同特性
这是它们提高ERK输出所需的信号。第二,升高的通路输出包括
生理信号通路的反馈抑制升高。这是一个重要的决定因素,
被称为癌蛋白依赖性。第三,反馈依赖的癌蛋白通路
依赖性降低了细胞的健壮性,并产生了对激活细胞的突变的选择。
反馈抑制途径并恢复鲁棒性。这说明了一些次要驱动因素
在肿瘤中发现的突变。最后,癌蛋白激活信号的抑制剂具有显著的
抗肿瘤活性,而且还减轻生理性促有丝分裂信号传导途径的反馈抑制,
导致它们重新激活。这减弱了它们的抗肿瘤活性,并创造了一种逻辑,
在暴露于癌蛋白抑制剂的肿瘤中重新激活通路。这一战略在早期已经有了一些
临床成功,并已成为开发合理组合疗法的范例。
尽管有这些见解,我们仍然只知道癌蛋白诱导的反馈及其作用的一些细节。
通过靶向抑制剂缓解。我们知道这些细节随着肿瘤谱系的变化而变化,
该途径组分被突变激活。此外,缓解反馈的效果也
取决于通路的哪个节点被抑制。我们现在计划
全面研究反馈及其缓解节点抑制剂,重点放在少数肿瘤和使用
这两种方法都受到以前对正常信号传导的了解的影响,并进行了无偏倚的shRNA筛选。
我们利用PI 3 K、AKT、mTOR、RAF、MEK、ERK的选择性抑制剂和一种新的等位基因特异性抑制剂。
RAS抑制剂和研究短期和长期适应,以确定是否有一些
后者的影响是由于表观遗传调节造成的。目标是开发新的有效组合
基于这些数据和体内研究的治疗,以确定优化
诱导细胞死亡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEAL ROSEN其他文献
NEAL ROSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEAL ROSEN', 18)}}的其他基金
Studies on oncoprotein-induced feedback: Basic and therapeutic implications
癌蛋白诱导反馈的研究:基本和治疗意义
- 批准号:
10247722 - 财政年份:2016
- 资助金额:
$ 102.84万 - 项目类别:
Studies on oncoprotein-induced feedback: Basic and therapeutic implications
癌蛋白诱导反馈的研究:基本和治疗意义
- 批准号:
9766084 - 财政年份:2016
- 资助金额:
$ 102.84万 - 项目类别:
Clinical Development of Next-Generation Antiandrogens and the Impact of PTEN Status
下一代抗雄激素的临床开发和 PTEN 状态的影响
- 批准号:
8730087 - 财政年份:2014
- 资助金额:
$ 102.84万 - 项目类别:
Developing therapeutic strategies for ERK-dependent tumors
开发 ERK 依赖性肿瘤的治疗策略
- 批准号:
8906506 - 财政年份:2013
- 资助金额:
$ 102.84万 - 项目类别:
Developing therapeutic strategies for ERK-dependent tumors
开发 ERK 依赖性肿瘤的治疗策略
- 批准号:
8741950 - 财政年份:2013
- 资助金额:
$ 102.84万 - 项目类别:
Developing therapeutic strategies for ERK-dependent tumors
开发 ERK 依赖性肿瘤的治疗策略
- 批准号:
8632319 - 财政年份:2013
- 资助金额:
$ 102.84万 - 项目类别:
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca
开发基于机制的晚期乳腺癌治疗策略
- 批准号:
7438486 - 财政年份:2008
- 资助金额:
$ 102.84万 - 项目类别:
Development of Methodologies for the In Vivo Imaging og the Effects of Novel Inhi
体内成像方法的开发和新型 Inhi 的效果
- 批准号:
7729470 - 财政年份:2008
- 资助金额:
$ 102.84万 - 项目类别:
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers
项目 2:针对 KRAS 和 BRAF 驱动的肺癌中的 ERK 通路
- 批准号:
10246297 - 财政年份:2007
- 资助金额:
$ 102.84万 - 项目类别:
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C
HSP90 作为去势抵抗性前列腺癌基于机制治疗的靶点
- 批准号:
7147036 - 财政年份:2005
- 资助金额:
$ 102.84万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 102.84万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 102.84万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 102.84万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 102.84万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 102.84万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 102.84万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 102.84万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 102.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 102.84万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 102.84万 - 项目类别: